Literature DB >> 25977309

Activating PPARα prevents post-ischemic contractile dysfunction in hypertrophied neonatal hearts.

Victoria H Lam1, Liyan Zhang1, Alda Huqi1, Arata Fukushima1, Brandon A Tanner1, Arzu Onay-Besikci1, Wendy Keung1, Paul F Kantor1, Jagdip S Jaswal1, Ivan M Rebeyka1, Gary D Lopaschuk2.   

Abstract

RATIONALE: Post-ischemic contractile dysfunction is a contributor to morbidity and mortality after the surgical correction of congenital heart defects in neonatal patients. Pre-existing hypertrophy in the newborn heart can exacerbate these ischemic injuries, which may partly be due to a decreased energy supply to the heart resulting from low fatty acid β-oxidation rates.
OBJECTIVE: We determined whether stimulating fatty acid β-oxidation with GW7647, a peroxisome proliferator-activated receptor-α (PPARα) activator, would improve cardiac energy production and post-ischemic functional recovery in neonatal rabbit hearts subjected to volume overload-induced cardiac hypertrophy. METHODS AND
RESULTS: Volume-overload cardiac hypertrophy was produced in 7-day-old rabbits via an aorto-caval shunt, after which, the rabbits were treated with or without GW7647 (3 mg/kg per day) for 14 days. Biventricular working hearts were subjected to 35 minutes of aerobic perfusion, 25 minutes of global no-flow ischemia, and 30 minutes of aerobic reperfusion. GW7647 treatment did not prevent the development of cardiac hypertrophy, but did prevent the decline in left ventricular ejection fraction in vivo. GW7647 treatment increased cardiac fatty acid β-oxidation rates before and after ischemia, which resulted in a significant increase in overall ATP production and an improved in vitro post-ischemic functional recovery. A decrease in post-ischemic proton production and endoplasmic reticulum stress, as well as an activation of sarcoplasmic reticulum calcium ATPase isoform 2 and citrate synthase, was evident in GW7647-treated hearts.
CONCLUSIONS: Stimulating fatty acid β-oxidation in neonatal hearts may present a novel cardioprotective intervention to limit post-ischemic contractile dysfunction.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  heart failure; hypertrophy; metabolism; therapy

Mesh:

Substances:

Year:  2015        PMID: 25977309     DOI: 10.1161/CIRCRESAHA.117.306585

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

1.  Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway.

Authors:  Guang-Zhong Liu; Ting-Ting Hou; Yue Yuan; Peng-Zhou Hang; Jing-Jing Zhao; Li Sun; Guan-Qi Zhao; Jing Zhao; Jing-Mei Dong; Xiao-Bing Wang; Hang Shi; Yong-Wu Liu; Jing-Hua Zhou; Zeng-Xiang Dong; Yang Liu; Cheng-Chuang Zhan; Yue Li; Wei-Min Li
Journal:  Br J Pharmacol       Date:  2016-02-18       Impact factor: 8.739

2.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 3.  Energy Metabolism on Mitochondrial Maturation and Its Effects on Cardiomyocyte Cell Fate.

Authors:  Kaya L Persad; Gary D Lopaschuk
Journal:  Front Cell Dev Biol       Date:  2022-07-05

4.  Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism.

Authors:  Arata Fukushima; Liyan Zhang; Alda Huqi; Victoria H Lam; Sonia Rawat; Tariq Altamimi; Cory S Wagg; Khushmol K Dhaliwal; Lisa K Hornberger; Paul F Kantor; Ivan M Rebeyka; Gary D Lopaschuk
Journal:  JCI Insight       Date:  2018-05-17

Review 5.  Cardiac Energy Metabolism in Heart Failure.

Authors:  Gary D Lopaschuk; Qutuba G Karwi; Rong Tian; Adam R Wende; E Dale Abel
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

6.  The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.

Authors:  Yan Huang; Corey Powers; Victoria Moore; Caitlin Schafer; Mindong Ren; Colin K L Phoon; Jeanne F James; Alexander V Glukhov; Sabzali Javadov; Frédéric M Vaz; John L Jefferies; Arnold W Strauss; Zaza Khuchua
Journal:  Orphanet J Rare Dis       Date:  2017-03-09       Impact factor: 4.123

7.  Aleglitazar, a dual peroxisome proliferator-activated receptor-α and -γ agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia.

Authors:  Yan Chen; Hongmei Chen; Yochai Birnbaum; Manjyot K Nanhwan; Mandeep Bajaj; Yumei Ye; Jinqiao Qian
Journal:  Diab Vasc Dis Res       Date:  2017-01-23       Impact factor: 3.291

8.  PPARα activation alleviates damage to the cytoskeleton during acute myocardial ischemia/reperfusion in rats.

Authors:  Jie Yuan; Hongdan Mo; Jing Luo; Suhong Zhao; Shuang Liang; Yu Jiang; Maomao Zhang
Journal:  Mol Med Rep       Date:  2018-03-16       Impact factor: 2.952

Review 9.  Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.

Authors:  Zaza Khuchua; Aleksandr I Glukhov; Arnold W Strauss; Sabzali Javadov
Journal:  Int J Mol Sci       Date:  2018-11-04       Impact factor: 5.923

10.  The Effects of PPAR Stimulation on Cardiac Metabolic Pathways in Barth Syndrome Mice.

Authors:  Caitlin Schafer; Vicky Moore; Nupur Dasgupta; Sabzali Javadov; Jeanne F James; Alexander I Glukhov; Arnold W Strauss; Zaza Khuchua
Journal:  Front Pharmacol       Date:  2018-04-11       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.